Aurobindo Pharma arm Acrotech Biopharma launches ADQUEY in US dermatology market. By Jomy Jos Pullokaran September 30, 2026, 10:26:52 PM IST (Published) Drug firm Aurobindo Pharma Ltd on Wednesday (September 30) said its biopharmaceutical arm Acrotech Biopharma Inc. has launched ADQUEY (difamilast 1%) ointment in the US for the treatment of mild-to-moderate atopic dermatitis in adults and paediatric patients aged 2 years and older. ADQUEY is a non-steroidal topical phosphodiesterase-4 (PDE4) inhibitor. The product will compete in a US market estimated at around $1.3 billion for the 12 months ended July 2026, according to IQVIA MAT. The launch marks Acrotech's entry into the US dermatology market. To support ADQUEY and its long-term dermatology plans, the company has established a dedicated dermatology business unit with commercial capabilities across marketing, sales and field-based engagement. The dermatology business will focus on building awareness of ADQUEY, engaging with dermatology healthcare professionals and supporting patients through their treatment journey. It will also develop the infrastructure and expertise required to expand Acrotech's presence in specialty dermatology. Difamilast was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for commercialisation in the US. The launch is part of Acrotech's strategy to expand its portfolio of innovative medicines and establish focused commercial platforms in areas of significant patient need. Ashish Anvekar, President of Acrotech Biopharma, said, "The launch of ADQUEY is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option for patients living with atopic dermatitis. We are building more than a commercial organisation around a single product. We are establishing a dedicated dermatology platform designed to support ADQUEY today while creating the capabilities to pursue additional opportunities that can address important unmet needs in dermatologic care." Shares of Aurobindo Pharma Ltd ended at ₹1,666.50, down by ₹36.50, or 2.14%, on the BSE.

Aurobindo Pharma's Acrotech enters US dermatology market with Adquey launch. Aurobindo Pharma (For representative purposes only) | Photo: Company website Aurobindo Pharma on Wednesday said its subsidiary Acrotech Biopharma launched the Adquey ointment in the US, marking its entry into the American dermatology market. The drug, a non-steroidal topical treatment for mild-to-moderate atopic dermatitis in adults and pediatric patients aged two years and above, was originally discovered by Otsuka Pharmaceutical and licensed to Acrotech Biopharma for commercialisation in the United States, Aurobindo Pharma said in a regulatory filing. To support the launch and expand this therapeutic segment, the company has set up a dedicated dermatology business unit, the filing said. The product will compete in a market estimated at around USD 1.3 billion for the 12 months ending July 2026, according to IQVIA MAT data. "The launch of Adquey is an important milestone for Acrotech and marks our entry into the US dermatology market with a differentiated treatment option," Acrotech Biopharma President Ashish Anvekar said. Acrotech Biopharma is a step-down subsidiary of Aurobindo Pharma Ltd formed as a global platform to commercialise innovative proprietary medications.